BACKGROUND: The acid-labile subunit (ALS) acts in the insulin-like growth (IGF) system by binding circulating IGF-I in a ternary complex with binding protein (IGFBP)-3 to prevent IGF-I from crossing the endothelial barrier. Given the role of the IGF system in prostate cancer, ALS may influence carcinogenesis by modulating IGF-I levels or bioavailability. METHODS: We undertook a prospective study nested in the Physicians' Health Study to examine ALS, free IGF-I, and prostate cancer. We assayed circulating levels of ALS and IGF components among 545 incident cases and 545 matched controls. We calculated relative risks (RR) and 95% confidence intervals (95% CI) adjusted for life-style factors, total IGF-I, and IGFBP3. RESULTS: ALS was positively correlated with total IGF-I (r = 0.58), IGFBP3 (r = 0.68), and free IGF-I (r = 0.36). Comparing highest versus lowest quartiles, we found no association between free IGF-I and prostate cancer risk (RR, 0.9; 95% CI, 0.6-1.3). In contrast, ALS was positively associated with risk among men in the 2nd (RR, 1.5; 94% CI, 1.0-2.3), 3rd (RR, 1.6; 94% CI, 1.1-2.5), and 4th quartiles (RR, 1.4; 94% CI, 0.9-2.1) compared with lowest quartile. The association was stronger for advanced stage tumors (RR, 2.0; 94% CI, 0.8-4.6). There was a suggestion of an interaction between ALS and total IGF-I, whereby high circulating IGF-I was associated with an increased risk of advanced prostate cancer among men with low but not higher ALS levels. DISCUSSION: Plasma ALS is positively associated with prostate cancer risk, and may interact biologically with IGF-I to affect carcinogenesis. These data provide further support for the role of the IGF axis in prostate cancer.
BACKGROUND: The acid-labile subunit (ALS) acts in the insulin-like growth (IGF) system by binding circulating IGF-I in a ternary complex with binding protein (IGFBP)-3 to prevent IGF-I from crossing the endothelial barrier. Given the role of the IGF system in prostate cancer, ALS may influence carcinogenesis by modulating IGF-I levels or bioavailability. METHODS: We undertook a prospective study nested in the Physicians' Health Study to examine ALS, free IGF-I, and prostate cancer. We assayed circulating levels of ALS and IGF components among 545 incident cases and 545 matched controls. We calculated relative risks (RR) and 95% confidence intervals (95% CI) adjusted for life-style factors, total IGF-I, and IGFBP3. RESULTS: ALS was positively correlated with total IGF-I (r = 0.58), IGFBP3 (r = 0.68), and free IGF-I (r = 0.36). Comparing highest versus lowest quartiles, we found no association between free IGF-I and prostate cancer risk (RR, 0.9; 95% CI, 0.6-1.3). In contrast, ALS was positively associated with risk among men in the 2nd (RR, 1.5; 94% CI, 1.0-2.3), 3rd (RR, 1.6; 94% CI, 1.1-2.5), and 4th quartiles (RR, 1.4; 94% CI, 0.9-2.1) compared with lowest quartile. The association was stronger for advanced stage tumors (RR, 2.0; 94% CI, 0.8-4.6). There was a suggestion of an interaction between ALS and total IGF-I, whereby high circulating IGF-I was associated with an increased risk of advanced prostate cancer among men with low but not higher ALS levels. DISCUSSION: Plasma ALS is positively associated with prostate cancer risk, and may interact biologically with IGF-I to affect carcinogenesis. These data provide further support for the role of the IGF axis in prostate cancer.
Authors: J V Lacey; A W Hsing; C M Fillmore; S Hoffman; K J Helzlsouer; G W Comstock Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-10 Impact factor: 4.254
Authors: June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2002-07-17 Impact factor: 13.506
Authors: Mari-Anne Rowlands; Jeff M P Holly; David Gunnell; Jenny Donovan; J Athene Lane; Freddie Hamdy; David E Neal; Steven Oliver; George Davey Smith; Richard M Martin Journal: Cancer Res Date: 2011-11-21 Impact factor: 12.701
Authors: Ke Zu; Neil E Martin; Michelangelo Fiorentino; Richard Flavin; Rosina T Lis; Jennifer A Sinnott; Stephen Finn; Kathryn L Penney; Jing Ma; Ladan Fazli; Martin E Gleave; Tarek A Bismar; Meir J Stampfer; Michael N Pollak; Massimo Loda; Lorelei A Mucci; Edward Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-27 Impact factor: 4.254
Authors: Sean Harrison; Rosie Lennon; Jeff Holly; Julian P T Higgins; Mike Gardner; Claire Perks; Tom Gaunt; Vanessa Tan; Cath Borwick; Pauline Emmet; Mona Jeffreys; Kate Northstone; Sabina Rinaldi; Stephen Thomas; Suzanne D Turner; Anna Pease; Vicky Vilenchick; Richard M Martin; Sarah J Lewis Journal: Cancer Causes Control Date: 2017-03-30 Impact factor: 2.506
Authors: Chaoran Ma; Ye Wang; Kathryn M Wilson; Lorelei A Mucci; Meir J Stampfer; Michael Pollak; Kathryn L Penney Journal: JNCI Cancer Spectr Date: 2021-12-15